Radiation and drug combo shows promise for tough liver cancers
NCT ID NCT07668570
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a combination of targeted radiation (SBRT) and an experimental drug called QL1706 in 36 adults with advanced liver cancer that has worsened after one prior treatment. The radiation is given to liver tumors over five sessions, followed by QL1706 infusions every three weeks. The goal is to see if this approach can shrink tumors and control the disease safely.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Stereotactic body radiation therapy (SBRT) and QL1706 (Iparomlimab and Tuvonralimab injection)
What this could lead to
If successful, this combination could offer a new second-line treatment option for liver cancer patients, potentially shrinking tumors and extending survival.
What could go wrong
This is a small, early-phase study with only 36 participants, so results may not apply to everyone. Side effects from radiation and the drug are possible, and the treatment may not work for all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.